- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/50 - Cellular immunotherapy characterised by the use of allogeneic cells
Patent holdings for IPC class A61K 40/50
Total number of patents in this class: 106
10-year publication summary
|
0
|
1
|
0
|
2
|
7
|
7
|
2
|
2
|
52
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Memorial Sloan-Kettering Cancer Center | 1980 |
5 |
| Allogene Therapeutics, Inc. | 155 |
4 |
| CRISPR Therapeutics AG | 373 |
3 |
| FATE Therapeutics, Inc. | 216 |
3 |
| Juno Therapeutics, Inc. | 463 |
3 |
| Iovance Biotherapeutics, Inc. | 352 |
3 |
| The Board of Trustees of the Leland Stanford Junior University | 6553 |
2 |
| The Johns Hopkins University | 5762 |
2 |
| The Trustees of the University of Pennsylvania | 4380 |
2 |
| Takeda Pharmaceutical Company Limited | 2707 |
2 |
| Cellectis | 406 |
2 |
| Fondazione Centro San Raffaele | 23 |
2 |
| Immunovative Therapies, Ltd. | 25 |
2 |
| Ospedale San Raffaele S.r.l. | 299 |
2 |
| Regents of the University of Minnesota | 2750 |
2 |
| Immatics US, Inc. | 60 |
2 |
| Century Therapeutics, Inc. | 41 |
2 |
| Angeles Therapeutics, Inc. | 14 |
2 |
| Board of Regents, The University of Texas System | 5966 |
1 |
| The General Hospital Corporation | 4800 |
1 |
| Other owners | 59 |